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INTRODUCTION
Mechanical ventilation is life-saving but it includes the risk
for ventilator-induced lung injury (VILI). The risk for VILI
increases when non-physiologic stress and strain is applied to the
lungs (1). Ventilation with high tidal volumes can lead to local
overdistension and pulmonary edema (2, 3). Ventilation with too
low tidal volume and low levels of PEEP can cause repetitive
opening and closing of alveoli thereby increasing shear stress
(4). Invasive mechanical ventilation also triggers local and
systemic release of inflammatory mediators (5, 6). Among the
inflammatory mediators are components of the complement
system present (7-9).
The complement system is an integral part of the innate
immune system and consists of more than thirty serum and cell
proteins (10). Activation of the complement cascade can be
triggered via the classical, the alternative, and the mannose-
binding lectin pathway (11-13). The three pathways converge to
the formation of C3 convertase (14). The C3 convertase cleaves
C3 in C3a and C3b, which contributes to the formation of C5a
and C5b. C5b initiates the formation of the terminal membrane
attack complex with consecutive cell lysis in a cascade-like
sequence (15). The split products C3a and C5a are collectively
called anaphylatoxins. Anaphylatoxins trigger inflammatory
effects like increased vascular permeability, enhanced white
blood cell chemotaxis and adherence to the pulmonary
endothelium with the subsequent release of lysosomal enzymes
and cytokines (16, 17).
Application of C1 esterase inhibitor (C1INH) is best known
as treatment for hereditary angioedema. C1INH strictly regulates
the classical pathway of the complement system and also
reduces the activation of the lectin pathway. Thereby, C1INH
offers the opportunity to examine to the contributions of both
activation pathways in VILI (18-21).
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The complement system contributes to ventilator induced lung injury (VILI). We hypothesized that pretreatment with the C1
esterase inhibitor (C1INH) Berinert® constrains complement activation consecutively inducing improvements in arterial
oxygenation and histological pulmonary damage. At baseline, male Sprague-Dawley rats underwent mechanical ventilation
in a conventional mode (PIP 13 cm H2O, PEEP 3 cm H2O). In the Control group, the ventilator setting was maintained
(Control, n = 15). The other animals randomly received intravenous pretreatment with either 100 units/kg of the C1-INH
Berinert® (VILI-C1INH group, n = 15) or 1 ml saline solution (VILI-C group, n = 15). VILI was induced by invasive
ventilation (PIP 35 cm H2O, PEEP 0 cm H2O). After two hours of mechanical ventilation, the complement component C3a
remained low in the Control group (258 ± 82 ng/ml) but increased in both VILI groups (VILI-C: 1017 ± 283 ng/ml; VILI-
C1INH: 817 ± 293 ng/ml; P < 0.05 for both VILI groups versus Control). VILI caused a profound deterioration of arterial
oxygen tension (VILI-C: 193 ± 167 mmHg; VILI/C1-INH: 154 ± 115 mmHg), whereas arterial oxygen tension remained
unaltered in the Control group (569 ± 26 mmHg; P < 0.05 versus both VILI groups). Histological investigation revealed
prominent overdistension and interstitial edema in both VILI groups compared to the Control group. C3a plasma level in the
VILI group were inversely correlated with arterial oxygen tension (R = – 0.734; P < 0.001). We conclude that in our animal
model of VILI the complement system was activated in parallel with the impairment in arterial oxygenation and that
pretreatment with 100 units/kg Berinert® did neither prevent systemic complement activation nor lung injury.
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So far, three investigations explored the role of the
complement system in experimental models of VILI (7-9). In a
study by Takahashi and colleagues, VILI caused a positive
pulmonary C3 staining in mice demonstrating that VILI induces
local complement activation (7). The complement component
C3 is formed after the conversion of the three activation
pathways leaving the initially triggering pathway unclear. Based
on enhanced CH50 plasma level Liu and co-workers concluded
that the classical pathway contributes to the complement
activation in VILI (8). DeBeer and colleagues further
investigated the role of the classical pathway of the complement
system using a clinically relevant double hit model in rats. After
40 hours of pulmonary Streptococcus pneumoniae infection, rats
underwent no ventilation, ventilation with low, or ventilation
with high tidal volumes, hence VILI (9). In the VILI group they
found an increased bronchoalveolar/serum ratio of C4b/c level
suggesting an activation of the classical and/or lectin pathway of
the complement system (9). However, the role of complement
system in a rat model of VILI might be interpreted with caution
since Streptococcus pneumoniae itself activates the classical and
alternative pathway of the complement system (22). Further, in
the study of deBeer and colleagues VILI was only mild with no
significant associated change in lung weight and arterial
oxygenation (9).
We also aimed at investigating the role of the classical and/or
lectin pathway of the complement system in VILI. In our study,
the rats received a single intravenous bolus of 100 mg/kg
Berinert® (VILI-C1INH) or saline (VILI-C) before VILI was
induced. An additional group of rats received conventional
mechanical ventilation and served as a further control (Control).
Mechanical ventilation was maintained for two hours. Arterial
blood gases and serum level of the complement component C3a
were measured to estimate the impact of the ventilator settings
on pulmonary gas exchange and complement activity,
respectively. At the end of the experiments, the lungs were
harvested for the measurement of wet lung weight and
histological examination.
MATERIALS AND METHODS
All animal experiments were approved by the Animal
Committee of the Erasmus University Medical Center
Rotterdam. Care and handling of the animals were in accordance
with the European Community guidelines. The study was
performed in 45 male Sprague-Dawley rats with a body weight
of 300 ± 30 g at the Department of Anesthesiology, Erasmus
University Medical Center Rotterdam, The Netherlands.
Preparation of the complement inhibitor C1 esterase inhibitor
A pasteurized human C1-INH (Berinert®, CSL Behring,
Marburg, Germany) was suspended with normal saline solution
to obtain a concentration of 30 U/ml. A dosage of 100 units/kg
was administered as a single bolus.
Animal preparation
After inhalative induction of general anesthesia with nitrous
oxide, oxygen and isoflurane (66/33/1-2%) the rats received an
intraperitoneal injection of pentobarbital sodium (Nembutal®,
Algin BV, Maassluis, The Netherlands; 60 mg/kg). A
polyethylene catheter (SIMS Portex, UK: 0.8 mm outer
diameter) was inserted into the carotid artery for arterial blood
sampling. The rats were tracheotomized and muscle relaxation
was achieved by intramuscular administration of pancuronium
bromide (Pavulon®, Organon, Boxtel, the Netherland; 2 mg/kg)
before connecting to the ventilator (Servo 300, Siemens-Elema
AB, Solna, Sweden). Up to six animals were mechanically
ventilated in parallel in a pressure controlled mode. At an
inspiratory oxygen fraction of 1.0 the ventilator settings were as
follows: peak inspiratory pressure (PIP) of 13 cm H2O, positive
end-expiratory pressure (PEEP) of 3 cm H2O, frequency of
breaths 30/minutes, and an inspiratory/expiratory ration of 1:2.
Anesthesia was continued by hourly intraperitoneal injections of
pentobarbital (60 mg/kg). Muscle relaxation was perpetuated
with intramuscular injections of pancuronium bromide (2
mg/kg) every hour. The body temperature was kept within
normal range with a heating lamp. To reopen atelectatic lung
areas PIP was increased to 26 cm H2O for six breathing circles
and reduced to 13 cm H2O thereafter. Five minutes later baseline
parameters were documented, and blood samples taken.
Animals were randomized to one of three groups (n = 15
each). The first group of animals was ventilated with a
conventional strategy (Control). The setting of mechanical
ventilation (PIP 13 cm H2O, PEEP 3 cm H2O) was maintained in
the Control group during the whole experiment. In the VILI
groups the ventilatory setting was changed as follows: PIP was
increased to 35 cm H2O and PEEP was decreased to 0 cmH2O.
Ventilatory frequency was kept stable at 30 bpm, and the dead
space (4 – ml) was increased to maintain a normal arterial carbon
dioxide tension. After baseline the Control group received a bolus
of 1 ml saline. The second group served as a control group for
ventilator induced lung injury (VILI-C). The rats received 1 ml
saline before VILI was started. To investigate the impact of the
C1INH on VILI the third group received a pretreatment with 100
units/kg Berinert® before the ventilatory setting was changed to
VILI (VILI-C1INH).
Blood gas analyses
At baseline, one and two hours later 0.5 ml blood were taken
anaerobically from the carotid artery catheter into heparinized
tubes and analyzed for blood gases (ABL 505, Radiometer,
Copenhagen, Denmark). The arterial blood gas analysis included
arterial oxygen tension (PaO2), arterial carbon dioxide tension
(PaCO2), arterial bicarbonate level (HCO3–a), and arterial pH
(pHa).
Plasma levels of the complement split product C3a
At the same three time points (baseline, one and two hours
later) 1.0 ml arterial blood samples were taken to measure the
plasma levels of the complement split product C3a. The samples
were immediately centrifuged at 3000 rpm for 10 minutes at
4°C. The plasma was stored at –20°C for later analyses. C3a
levels were determined by the commercially available C3a-
enzyme-linked immunosorbent assay for rat (Dianova,
Hamburg, Germany).
Morphological investigations
At the end of the protocols, the animals were sacrificed with
an intravenous overdose of pentobarbital. The lungs were
removed, prepared and weighted wet. Subsequently, the lungs
were fixed in 4% paraformaldehyd, processed through graded
alcohol and embedded in Paraplast (Monojest Scientific, St.
Louis, USA). Sections of 4 µm were stained with hematoxylin
and eosin for routine histological assessment. The histological
parameters included atelectasis, overdistension and necrosis.
Bleeding, edema and inflammation were evaluated in the
interstitial and alveolar compartment. Cell infiltration was
further examined for bacteria and eosinophils. Each variable was
evaluated using a 0- to 4-point scale corresponding to an injury
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in 0%, 25%, 50%, 75%, or 100% of the investigated tissue,
scoring 0, 1, 2, 3, and 4, respectively. The slices were evaluated
by a pathologist who was blinded to the animal's group
assignment.
Statistical analyses
All data are expressed as mean ± S.D. All calculations were
performed using a standard statistical program (SPSS 20.0, IBM
Corporation, Armonk, New York, USA). Statistical significance
was accepted at P-values < 0.05. ANOVA was used to assess
differences between the groups. Differences within a group were
analyzed by the means of ANOVA for repeated measures.
Significant differences of the lung injury score data were
detected by the Kruskal-Wallis nonparametic test. In all cases
post hoc multiple comparisons were performed using the
Bonferroni test. Correlation analysis of C3a plasma level and
PaO2 values of the VILI group was performed with the
Spearman rank correlation coefficient.
RESULTS
C1 esterase inhibitor did not improve pulmonary gas exchange
in VILI
Induction of VILI was associated with a three-fold increase
of the lung tidal volume in the VILI-C and VILI-C1INH group
compared to the Control group (both VILI groups: 37 ± 3 ml/kg;
Control: 12 ± 1 ml/kg; values at the end of the protocol).
Arterial blood gas tensions were measured at baseline as
well as one and two hours later in the Control-, VILI-C, and
VILI-C1INH group (Fig. 1, Table 1). The measured values of the
arterial oxygen partial pressure (PaO2) were identical to
PaO2/FiO2 quotients since the animals were ventilated with
100% oxygen (FiO2 1.0) throughout the protocol. At baseline
PaO2 did not differ between the groups. VILI induced a marked
decrease in arterial oxygenation. After one hour, the PaO2
decreased in the VILI-C1INH group compared to baseline (P <
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Fig. 1. Arterial oxygenation
during the protocol in
conventionally ventilated
Controls (Control, n = 15) and in
animals with VILI induced after
baseline (0 min) and pretreated
either with saline (VILI-C, n =
15) or the C1-esterase inhibitor
(VILI-C1INH, n = 15). VILI
resulted in a significant and
sustained decrease in arterial
oxygenation. *P < 0.05 versus
Control; §:P < 0.05 versus
baseline (0 min) of the respective
group; †P < 0.05 versus 1 hour
within the respective group.
Table 1.  Arterial blood gas analyses during the protocol.  
Parameter Group Baseline  1 hour 2 hours 
PaCO2  Control 35 ± 6 37 ± 5 43 ± 11 
(mmHg) VILI-C 31 ± 5 38 ± 12  52 ± 23 §† 
  VILI-C1INH 33 ± 7 47 ± 15 § 68 ± 17 *§† 
    
HCO3
-
a  Control 27 ± 3 26 ± 3 27 ± 2 
(mmol/l) VILI-C 28 ± 2 26 ± 3 §  20 ± 6 *§† 
  VILI-C1INH 26 ± 3 26 ± 4 23 ± 4 *§† 
    
pHa  Control 7.49 ± 0.06 7.45 ± 0.06 § 7.42 ± 0.08 § 
  VILI-C 7.55 ± 0.06 7.45 ± 0.10 § 7.23 ± 0.13 *§†
VILI-C1INH 7.52 ± 0.08  7.38 ± 0.10 § 7.16 ± 0.08 *§†
PaCO2, arterial carbon dioxide tension; HCO3–a: arterial bicarbonate level; pHa, arterial pH. N = 15 in each group.*: P < 0.05 versus
Control; § P < 0.05 versus baseline of the respective group; † P < 0.05 versus 1 hour of the respective group.
Table 1. Arterial blood gas analyses during the protocol.
0.05). Two hours of VILI caused a further decrease of the PaO2
values in VILI-C and VILI-C1INH groups (P < 0.05 versus
baseline and P < 0.05 versus Control for both VILI groups).
There was no difference in the values of arterial partial
pressure of carbon dioxide (PaCO2) between the three groups at
baseline. VILI resulted in increased PaCO2 values. During the
protocol PaCO2 increased in the VILI-C and in the VILI-C1INH
group. At 2 hours PaCO2 values were in both VILI groups
significantly different when compared to baseline and the
Control group.
The arterial bicarbonate values were comparable at baseline
between the three groups. In Controls the bicarbonate levels
remained stable during one and two hours of ventilation whereas
the bicarbonate levels decreased in the VILI-C group after one
and two hours when compared to baseline (P < 0.05 for both).
After two of ventilation the bicarbonate values were significantly
reduced in both, the VILI-C and the VILI-C1INH group when
compared to values at baseline and values in Controls.
The arterial pH values in the Control group were lower after
one and two hours of ventilation compared to baseline (P < 0.05
for both). There was a significant reduction in the pH values of
the VILI-C and VILI-C1INH group at 1 and 2 hours when
compared to baseline (P < 0.05 for both VILI groups).
Comparison between the groups revealed lower pH values in the
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Fig. 2. Plasma levels of the
complement split product C3a
during the protocol of
conventionally ventilated
Controls (Control, n = 15) and
in animals with VILI induced
after baseline (0 min) and
pretreated either with saline
(VILI-C, n = 15) or Berinert®
(VILI-C1INH). VILI caused a
clear and significant increase in
C3a plasma levels which was
not prevented by Berinert®
application. *P < 0.05 versus
Control; §P < 0.05 versus
baseline (0 min) within the
respective group; †P < 0.05
versus 1 hour of the respective
group.
Fig. 3. The figure shows the
arterial oxygenation and C3a
plasma level at baseline as well
as after one and two hours of
VILI (n = 15 for each time-
point). A statistically significant
substantial inverse correlation
between the arterial oxygen
tensions and the level of systemic
complement activation is present
(R = –0.734; P < 0.001).
VILI-C and in the VILI-C1INH group at 2 hours when compared
to the Controls (P < 0.05 for both VILI groups).
Release of high plasma levels of the complement split product
C3a in VILI
The plasma levels of the complement split product C3a did
not differ between the groups at baseline (Control: 251 ± 64 ng/ml,
VILI-C: 300 ± 138 ng/ml, VILI-C1INH: 292 ± 79 ng/ml; Fig. 2).
In the Control group the plasma C3a values remained at constant
levels after one and two hours (260 ± 85 ng/ml and 258 ± 82
ng/ml, respectively). In contrast, the plasma C3a concentration
markedly increased in the VILI-C and VILI-C1INH group after
one hour (VILI-C: 569 ± 222 ng/ml, VILI-C1INH: 600 ± 206; P
< 0.05 compared to Control for both) and at two hours (VILI-C:
1017 ± 283 ng/ml, VILI-C1INH: 817 ± 293 ng/ml; P < 0.05
compared to Controls for both groups). Further, intra group
comparisons of the C3a values revealed a significant increase
from baseline within the VILI-C and the VILI-C1INH group at
one and two hours (P < 0.05 for both VILI groups).
Plasma level of C3a correlate with arterial oxygen tensions in
VILI
VILI induced high level of the complement split product
C3a and decreased arterial oxygenation. The statistical analysis
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Fig. 4. Wet lung weights were
measured at the end of the
experiments. VILI caused a
significant increase in wet lung
weight after pretreatment with
either saline (VILI-C, n = 15) or
C1INH (VILI-C1INH, n = 15)
compared to conventionally
ventilated rats (Control, n = 15).
*P < 0.05 versus Control.
Fig. 5. Lung tissue was stained with hematoxylin & eosin and examined under light microscopy. Panel A: representative slide of
the Control group with atelectasis (black arrow) and some interstitial inflammatory cells (white arrow); magnification × 200. Panel
B: representative slide of the VILI group with profound overdistension (black arrow) and interstitial edema (white arrow);
magnification × 200.
revealed a substantial inverse correlation between C3a plasma
level and PaO2 values (R = –0.765, P < 0.001) suggesting that
enhanced complement activation is associated with a
deterioration of arterial oxygenation (Fig. 3).
A single dose of the C1 esterase inhibitor did not prevent lung
tissue damage in VILI
VILI caused a profound increase in wet lung weight in the
VILI-C (2.92 ± 0.50g) and VILI-C1INH (2.83 ± 0.25g) group
compared to Controls (1.68 ± 0.45g; P < 0.05 for both
comparisons; Fig. 4).
Atelectases occurred only in Controls and were absent in
VILI-C and VILI-C1INH group (P < 0.05 versus Control for
both VILI groups; Fig. 5a). The most prominent features of the
histological examination were interstitial edema and alveolar
overdistension in the VILI-C and VILI-C1INH group compared
to Controls (P < 0.05 for both parameters in VILI-C and VILI-
C1INH, Fig. 5b). In all three groups interstitial bleeding and to
a minor degree alveolar bleeding were present. Evaluation of
inflammation showed no difference between the groups.
Scattered inflammatory cells were present in the interstitium but
nearly absent in the alveoli. No bacteria and eosinophils were
detectable. Data of the lung tissue score are presented in Table 2.
DISCUSSION
In our study we intended to investigate the classical and / or
lectin pathway of the complement system by the pre-treatment
with 100 mg/kg of the inhibitor C1 esterase inhibitor Berinert®
in VILI. We found that VILI caused significant systemic
complement activation that was inversely correlated with arterial
oxygenation. Pretreatment with a single dose of C1INH had no
beneficial effects on systemic complement activation,
pulmonary gas exchange or lung tissue damage.
Our study included the impact of VILI on complement
activation and arterial blood gas tensions. Mechanical
ventilation was scheduled for two hours to facilitate repetitive
blood samples. VILI was induced by an inspiratory peak
pressure 35 cm H2O and end-expiratory pressure of 0 cm H2O.
The ventilator setting was chosen based on previous
investigations showing that ventilation with a tidal volume of 40
ml/kg without positive end-expiratory pressure induces
inflammatory mediator expression and impairs arterial
oxygenation within two hours of ventilation (23-25).
C1 esterase inhibiton blockades mainly the classical pathway
and in part the lectin pathway of the complement system thereby
offering the opportunity to clarify the role of these pathways in
VILI-induced complement activation (26). In our rodent model of
VILI, pretreatment with 100 units/kg Berinert® failed to inhibit
systemic complement activation which could be related to various
reasons. First, Berinert® is extracted out of human plasma. The
efficiency of human C1INH might be less than the natural rat
analogue. We feel, however, that the above arguments are put into
perspective since human C1 esterase inhibitor has been proven to
affect complement activation in serum of male Sprague-Dawley
rats (27). Secondly, the single dosage might have been too small to
be effective. It is short-coming of our study that we did not perform
a dose-response investigation in our VILI model. Nevertheless,
Berinert® in doses of 50 and 100 U/kg has been demonstrated to
sufficiently inhibit activation of the classical pathway of the
complement system in rat model of ischemia reperfusion injury
(27). Based on this results our dose of 100 U/kg was chosen.
Thirdly, the protective effects of C1INH might depend on
inflammatory cell infiltration. On the one hand, in thermal injury
and ischemia reperfusion injury, the successful inhibition of
complement activation was associated with reduced neutrophil
infiltration (27, 28). On the other hand, in the double hit model of
streptococcus pneumonia infection and mandatory ventilation,
VILI was associated with increased pulmonary neutrophil influx,
but treatment with the C1INH failed to diminish inflammatory cell
infiltration (9). Fourthly, the complement system can be activated
via the classical, lectin and alternative pathway. C1INH inhibits the
classical and constrains the lectin pathway so that activation of the
alternative pathway or its amplification loops might have
overwhelmed the inhibitory capacity of C1INH.
Because we cannot exclude the above listed arguments for the
failure of 100 mg/kg Berinert® to inhibit systemic complement,
the discussion focuses on the results of the VILI-C group. The
complement system can be activated via the classical, lectin and
alternative pathway. The studies by Liu, deBeer, and colleagues
showed that VILI induces the classical pathway of the
complement system (8, 9). However, the alternative pathway can
be activated via distracted host cells (29). In our study the
histological sections show overdistension as a prominent feature
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Control VILI-C VILI-C1INH
Interstitial bleeding 1.4 ± 0.5 1.4 ± 0.6 1.2 ± 0.9 
Alveolar bleeding 0.6 ± 0.6 0.9 ± 0.5 0.7 ± 0.5 
Overdistension 0.1 ± 0.4 1.4 ± 1.1* 1.9 ± 0.6* 
Atelectasis 2.5 ± 1.1 0.2 ± 0.6* 0.2 ± 0.4* 
Necrosis 0 0 0 
Interstitial edema 0 1.6 ± 1.0* 2.3 ± 0.5* 
Alveolar edema 0 0.6 ± 0.8 0 
Interstitial inflammation 2.3 ± 1.0 1.6 ± 0.7 1.9 ± 0.3 
Alveolar inflammation 0.1 ± 0.4 0 0 
Eosinophils 0 0 0 
Bacteria 0 0 0 
Histological examination of lung sections after two hours of mechanical ventilation. The rats were subjected to conventionally
ventilation (Control) or ventilator-induced lung injury treated with saline (VILI-C) or treated with C1 esterase inhibitor (VILI-C1INH);
n = 15 in each group. *P < 0.05 versus Control.
Table 2. Histological lung tissue score at the end of the protocol.
in both VILI groups supporting a possible activation of alternative
pathway. Furthermore, the alternative pathway functions primarily
as an amplifying process resulting in increased C3b and
consecutively C3a levels within minutes (30). Taken together, it
appears reasonable that VILI activates both, the classical and the
alternative pathway of the complement system. The inefficiency
of C1INH pretreatment on complement activation and lung injury
in the study by deBeer and in our study may also support the
relevance of the alternative pathway since C1INH mainly inhibits
the classical and in part the lectin pathway (9).
The three activation pathways converge at the level of C3.
VILI causes positive pulmonary C3 demonstrating local
complement activation (7). In our study VILI induced increased
plasma C3a level supporting VILI-induced systemic
complement activation. To explore the functional relevance of
complement activation on arterial oxygenation, C3a plasma
level and arterial oxygen tensions were measured after one and
two hours of VILI. Statistical analysis revealed that the level of
complement activation was substantially correlated with the
deterioration of arterial oxygenation in our rat model of VILI.
The anaphylatoxins C3a and C5a cause increased
chemotaxis of neutrophils (16, 17). In double hit model of
pneumonia and mechanical ventilation, VILI was associated
with enhanced complement activation and increased pulmonary
neutrophil influx leaving the contribution of pneumonia- or
anaphylatoxins-induced neutrophil recruitment unclear (9). In
our study the histological sections did not show differences in
cell infiltration between the groups suggesting that neutrophils
are not mandatory to activate the complement system in VILI.
The proteolytic cascade of the complement system finally
leads to the formation of the membrane attack complex C5b6789
(15). In rat pulmonary microvascular endothelial cell cultures, Liu
and co-workers showed that C5b6789 contributes to increased
vascular permeability and thus pulmonary edema (8). In addition,
the anaphylatoxins C3a and C5a are known to increase vascular
permeability (16, 17). In accordance, we found increased C3a
plasma level, increased wet lung weight and profound interstitial
edema in the VILI group. However, the main determinant of
pulmonary edema is the pulmonary strain caused by mechanical
ventilation (1, 31). In this line, overdistension was a prominent
feature in the histological sections of the VILI group. The results
collectively indicate that the activated complement system might
contribute to the strain-induced pulmonary edema in VILI.
In summary, our study confirms that VILI causes systemic
complement activation since increased C3a plasma level were
paralleled by deterioration of arterial oxygenation. The histological
sections of the Control and VILI groups did not reveal differences
in inflammation suggesting that the complement system
contributes to pulmonary edema independently of cell infiltration.
The failure of the pretreatment with 100 mg/kg Berinert® to
prevent systemic complement activation, deterioration of arterial
oxygenation or lung tissue damage confirms the results of deBeer
and colleagues (9) and might point towards the alternative pathway
of the complement system. Further studies should clarify the
primary activation pathway of the complement system in VILI.
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